Group 1 - The company held its second board meeting of the seventh session on August 18, 2025, with all nine directors present, and the meeting was deemed legally valid [2][3]. - The board approved a proposal to reduce the total amount of funds raised through a simplified procedure for issuing shares to specific targets from 175.29 million yuan to 125.29 million yuan [3][7]. - The number of shares to be issued was adjusted from 12,785,769 shares to 9,138,795 shares, which does not exceed 30% of the company's total share capital before the issuance [4][6]. Group 2 - The adjusted total amount of funds to be raised is 125.29 million yuan, which is still within the limit of 300 million yuan and does not exceed 20% of the company's net assets at the end of the previous year [7][26]. - The net proceeds from the fundraising will be invested in projects related to vaccine research and production, with the company allowed to adjust the investment sequence and amounts based on actual needs [6][34]. - The board also approved a feasibility analysis report regarding the use of funds raised through the issuance of shares, confirming that the funds will be used for projects in the field of technological innovation [12][18]. Group 3 - The company has committed to measures to mitigate the dilution of immediate returns resulting from the share issuance, including maintaining stable business growth and accelerating project investment [40][46]. - The company has a strong talent reserve, with a stable management team and ongoing recruitment efforts to enhance its human resources [36]. - The company has established a comprehensive technical reserve, focusing on vaccine research and development, and has formed partnerships with academic institutions to enhance its innovation capabilities [37][38]. Group 4 - The company plans to strengthen its fundraising management to ensure compliance and effective use of the raised funds, with regular checks and disclosures on fund usage [42]. - The company aims to accelerate the construction of fundraising investment projects to enhance its competitiveness and sustainable development [43]. - The company has developed a profit distribution policy to ensure stable returns for investors, particularly small and medium shareholders [44][45].

Group 1 - The first domestically produced nine-valent HPV vaccine "Xinkening®9" has been approved for market release, priced at 499 yuan per dose, approximately 40% of the price of imported nine-valent HPV vaccines [2] - The vaccine was developed by a team led by Academician Xia Ning Shao from Xiamen University in collaboration with Wantai Biological Pharmacy, utilizing a novel prokaryotic expression system [2][3] - The development process took 18 years, involving over 20 PhD and 150 master's degree holders from Wantai Biological, marking a significant breakthrough in China's biopharmaceutical sector [2][3] Group 2 - Clinical trial results published in The Lancet Infectious Diseases indicate that "Xinkening®9" shows similar immune response and safety profiles compared to imported vaccines [3] - The vaccine effectively prevents persistent infections from seven high-risk HPV types associated with cervical cancer, establishing a protective barrier for women aged 18-45 [3] - The World Health Organization has initiated a global strategy to accelerate the elimination of cervical cancer, with China also launching an action plan that includes promoting HPV vaccination as a key objective [3] Group 3 - Wantai Biological has invested approximately 1 billion yuan in the research and development of the nine-valent HPV vaccine, with the approval of its market license expected to enhance the company's product line and core competitiveness [4] - The introduction of the domestically produced vaccine is anticipated to increase vaccination rates among eligible women, contributing to the establishment of a national immunity barrier against cervical cancer [4][5] - The affordable pricing of the vaccine is expected to benefit over 100 million women in China and positively impact global efforts to combat cervical cancer [5]